In the collaboration, Pepscan will use its proprietary Clips technology to identify functional mimics of the essential parts of intractable targets. These mimics will be used by Genmab to create and select unique therapeutic antibodies using its fully human monoclonal antibody technology. Intractable targets include those that are difficult to address using commonly available technologies but are highly desirable for targeting with monoclonal antibodies.
Joost van Bree, CEO of Pepscan Therapeutics said: “Monoclonal antibodies against intractable targets are a significant unmet need. The combination of Pepscan Clips protein mimicry platform with Genmab’s ability to generate fully human monoclonals will enable the partners to develop innovative products for poorly served indications.”